The retail turnover (including VAT) of Apranga Group amounted to EUR 21.0 million in February 2025 and decreased by 4.0% compared to February 2024. The decline in retail turnover of Apranga Group in February 2025 was influenced by the one-day shorter February and weaker-than-usual sales of the spring season collection due to colder weather. In January-February 2025, the retail turnover of Apranga Group (including VAT) totalled EUR 46.9 million and increased by 2.0% year-on-year. In January-February 2025, the retail turnover of Apranga Group in Lithuania increased by 2.7%, in Latvia increased by 2.8% and in Estonia decreased by 2.6% year-on-year. Currently Apranga Group operates the chain of 169 stores (102 in Lithuania, 43 in Latvia and 24 in Estonia) covering an area of 91.6 thousand sq. m. Stores area increased by 1.2% year-on-year. Rimantas...

A Media Snippet accompanying this announcement is available by clicking on this link. LONDON, March 03, 2025 (GLOBE NEWSWIRE) — Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, today announced it has renewed its multi-year partnership with UEFA, with Getty Images continuing to serve as UEFA’s official appointed photographic agency. The agreement will see Getty Images’ award-winning sports photographers and editors provide comprehensive coverage of all UEFA men’s and women’s club and national team competitions, including the UEFA Champions League, UEFA Europa League, the new UEFA Women’s Europa Cup starting in the 2025/2026 season, and the UEFA Futsal EURO. Alongside its matchday coverage of the UEFA Champions League, Getty Images will provide UEFA and its commercial partners with an expanded...

The new entity, NITO Renewable Energy, Inc., to hold all current and future solar operations of the Company Neve Yarak, Israel, March 03, 2025 (GLOBE NEWSWIRE) — N2OFF, Inc. (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech, announced today the establishment of a new wholly-owned US subsidiary, NITO Renewable Energy, Inc., that is registered in Nevada. The new entity will focus and consolidate the Company’s current and future Solar PV activities. The Company is currently invested in 3 projects in two countries in Europe. Germany: The joint venture is developing a 111 MWp solar photovoltaic (PV) project in Melz, Germany. This project has secured municipal approval and an indicative grid connection solution from a regional energy service...

Program provides up to $150,000 to support up-and-coming filmmakers and drive a new generation of talent Submissions open March 10, Five winners selected by award-winning creators David Lowery, Charlotte Wells, Sean Wang, Savanah Leaf and Adam Bricker, ASC. NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) — Vimeo, the world’s most innovative video experience platform for creators and enterprises, today announced the launch of the first-ever “Vimeo Short Film Grant presented by Nikon | RED.” This initiative will empower emerging filmmakers to bring their creative visions to life with the support and mentorship of industry visionaries, class-leading equipment, and distribution to Vimeo’s vast global audience. The grant will award five filmmakers with $30,000 each in funding to produce a short film, along with one-on-one mentorship...

Conference Call and Webcast Scheduled for March 13, 2025 at 2:00 p.m. PT/5:00 p.m. ETSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the fourth quarter and full year 2024 financial results and provide a business update on March 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. Listen-Only WebcastThe listen-only webcast will be made available on the Company’s website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company’s...

REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call Information When: Monday, March 10, 2025, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BIddb737c625d842e0867fa22a43106197 Webcast: https://edge.media-server.com/mmc/p/3dwbidfe The press release with the fourth...

Empowering Mobile Operators and Service Providers toRapidly Launch and Monetize Consumer Cloud Services BRIDGEWATER, N.J., March 03, 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss”) (NASDAQ: SNCR), a global leader in personal cloud solutions, today introduced Capsyl Cloud™, a new turn-key personal cloud platform designed for mobile operators and broadband service providers worldwide. Capsyl Cloud expands Synchronoss’s cloud portfolio, enabling service providers to launch secure, scalable, and revenue-generating personal cloud services with minimal deployment time. Synchronoss will showcase live demonstrations of Capsyl Cloud at MWC Barcelona in Executive Suite [3A19EX], providing a first-hand look at how operators can rapidly deploy and monetize branded cloud services. Capsyl Cloud is a secure, cross-platform...

Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids, Alcohol, Cocaine and Methamphetamine HOUSTON, TX, March 03, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled “Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder (OUD) and Substance Use Disorder (SUD).” This newly allowed patent covers Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology, a non-invasive, drug-free...

Interim President & CEO Jim Janik Returning to Role as Chairman of the Board of Directors MILWAUKEE, March 03, 2025 (GLOBE NEWSWIRE) — Douglas Dynamics, Inc. (NYSE: PLOW), North America’s premier manufacturer and upfitter of work truck attachments and equipment, today announced the Board of Directors has appointed Mark Van Genderen as President and Chief Executive Officer (CEO), effective immediately. He will also join the Board of Directors effective immediately. Mr. Van Genderen has been with the company for five years, and most recently served as Chief Operating Officer and President of Work Truck Attachments. He succeeds Interim President & CEO, James (Jim) L. Janik, who will return to his former role as Chairman of the Board of Directors. “Over the past five years, Mark has developed a deep understanding of...

– CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin –– Phase 1 study in healthy volunteers ongoing – HAMPTON, N.J., March 03, 2025 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive preclinical data from CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis—thymic stromal lymphopoietin (TSLP) and mast cell depletion via stem cell factor (SCF) starvation. The data demonstrate that CDX-622 neutralizes both SCF and TSLP, reducing tissue mast cells and inhibiting Type 2 inflammatory responses, supporting its potential to improve clinical activity over single target inhibition in inflammatory diseases and fibrotic disorders. The data were presented by Diego Alvarado, PhD,...